---
title: "Tilray Earnings Preview: What to expect"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293954122.md"
description: "Tilray (TLRY) is set to report Q4 earnings with consensus EPS of $0.21 and revenue of $246.3M, up 9.7% YoY. Analysts highlight strong international growth (~73% YoY in Q3) and the HelloMD acquisition for vertical integration. Investors will focus on whether international momentum continues, potential US market entry upon rescheduling, and updates on fiscal 2026 EBITDA guidance ($62M-$72M). Roth Capital recently upgraded the stock to Buy."
datetime: "2026-07-27T15:47:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293954122.md)
  - [en](https://longbridge.com/en/news/293954122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293954122.md)
generator: "portal-rs"
---

# Tilray Earnings Preview: What to expect


### Related Stocks

- [TLRY.US](https://longbridge.com/en/quote/TLRY.US.md)

## Related News & Research

- [Tilray lifts annual cannabis cultivation capacity to 275 metric tonnes to meet international medical demand](https://longbridge.com/en/news/296478526.md)
- [Tilray Medical calls for German law to codify guidance on prescribing standardized full-spectrum cannabis extracts](https://longbridge.com/en/news/296217801.md)
- [XORTX Therapeutics Inc. GAAP EPS of -$1.05](https://longbridge.com/en/news/296650983.md)
- [Tilray’s BrewDog launches 2026 advent calendar priced at £51.99](https://longbridge.com/en/news/296221263.md)
- [Workday stock is downgraded after buyout report as growth expectations are 'too optimistic'](https://longbridge.com/en/news/296104750.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**